Gary Gustafson

Drug delivery across the blood-brain barrier has relied on passive diffusion of small-molecule drugs. A new CAS analysis shows that several other methods are having success in clinical development and could open new ways to treat conditions of the central nervous system.

Neuroinflammation is a known symptom of diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis, but it’s also a driver in disease progression. This insight is leading to new therapeutic targets to reduce neuroinflammation.

Small molecule PPI inhibitors are on the brink of improving cancer treatments

CAS and Totus Medicines discuss how targeted covalent inhibitors are revolutionizing cancer treatments.